UpHealth reported FY 2025 results with a net loss attributable to shareholders of SGD 1.4 million, compared with a FY 2024 net loss of SGD 22.7 million. For H2 2025, it posted profit attributable to shareholders of SGD 0.3 million, versus a H2 2024 loss of SGD 8.9 million. Basic and diluted EPS was -0.91 cents for FY 2025 and 0.21 cents for H2 2025. The group recorded no revenue from discontinued operations in FY 2025, following the completion of its agriculture business disposals in July 2024. Finance income rose to SGD 5.1 million in FY 2025 (+51.6%), while FY 2025 finance costs were SGD 0.2 million (-71.7%) and administrative expenses were SGD 6.1 million (-10.1%). Total assets were SGD 69.1 million at 31 December 2025, with cash and cash equivalents of SGD 24.7 million and total equity of SGD 67.4 million. On corporate developments, UpHealth changed its name from Don Agro International to UpHealth Group Limited effective 30 January 2026, and said it completed the acquisition of 812 Capital and Centre for Innovative Medical Technologies (Euroonco oncology clinics) on 12 February 2026, exiting “cash company” status; the medical business is expected to be consolidated from the six months ending 30 June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UpHealth Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: B9EZFBBE2RNIU6N7) on March 01, 2026, and is solely responsible for the information contained therein.